Company Filing History:
Years Active: 1982-2002
Title: The Innovative Contributions of Jan Ulmius
Introduction
Jan Ulmius is a distinguished inventor based in Lund, Sweden, who has made significant strides in the field of pharmaceutical innovations. With a total of three patents to his name, Ulmius has focused primarily on the treatment of inflammatory bowel diseases, contributing valuable methodologies and compositions to this vital area of medical research.
Latest Patents
Ulmius's latest patents showcase his expertise in addressing inflammatory conditions affecting the bowel. The first patent, "Method for the treatment of inflammatory bowel diseases," details methods involving the oral administration of budesonide specifically for the treatment of ulcerative colitis and Crohn's colitis. These methods not only target the active phase of these diseases but also serve as relapse prevention for Crohn’s disease in its chronic phase and small intestine. His second patent, "Oral composition for the treatment of inflammatory bowel disease," describes an oral pharmaceutical composition designed for targeted slow release. This innovative composition enables effective treatment for various areas of the intestinal tract impacted by ulcerative colitis and certain aspects of Crohn's disease.
Career Highlights
Jan Ulmius has worked with prominent companies such as Aktiebolaget Draco and Astra Aktiebolag, where he honed his skills in pharmaceutical development and innovation. His work in these companies has allowed him to explore new avenues in treating bowel diseases, thereby improving the lives of countless patients.
Collaborations
Throughout his career, Ulmius collaborated with esteemed colleagues, including Karl O. Bergstrom and Bo L. Wenngren. These partnerships have contributed to the advancement of his research and innovations, facilitating a deeper understanding of inflammatory bowel diseases and their treatment options.
Conclusion
Jan Ulmius stands out as a noteworthy inventor in the pharmaceutical landscape. His innovative patents, combined with his collaborative efforts and career experiences, reflect his dedication to enhancing treatment protocols for inflammatory bowel diseases. As he continues to develop new solutions, Ulmius remains a key figure in innovations that seek to improve patient outcomes in the field of gastroenterology.